Oestrogel

How to order Oestrogel

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Oestrogel on Prescriptsy

Oestrogel is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Oestrogel is a transdermal hormone replacement therapy (HRT) gel containing estradiol 0.06% (0.75 mg per measured dose).

It is applied once daily to the skin, where it is absorbed into the bloodstream to relieve menopausal symptoms including hot flushes, night sweats, vaginal dryness, and sleep disturbance.

Oestrogel provides oestrogen only; women with an intact uterus must also take a separate progestogen to protect the womb lining.

Oestrogel is a prescription-only medicine (POM) in the United Kingdom, manufactured by Besins Healthcare.

Transdermal oestrogen preparations, including gels, have become increasingly popular in the UK following publication of evidence showing important safety advantages over oral HRT, particularly regarding the risk of blood clots.

NICE guideline NG23 (Menopause: diagnosis and management) recommends considering transdermal HRT for women with risk factors for venous thromboembolism, including obesity, personal or family history of VTE, and thrombophilia.

This page provides a detailed clinical guide to Oestrogel, covering how it works, application instructions, side effects, safety warnings, and how to obtain a prescription in the United Kingdom.

Important safety information about Oestrogel

Before reading further, please note these essential safety points.

• Oestrogel provides oestrogen only. If you have a uterus, you must also take a progestogen to prevent endometrial hyperplasia and cancer.
• Transdermal HRT carries a lower risk of blood clots than oral HRT, but you should still discuss your individual risk factors with your prescriber.
• Allow the gel to dry completely before skin contact with others, particularly children. Accidental transfer can cause hormonal effects.
• Report unscheduled vaginal bleeding to your prescriber, especially if it occurs after the first 6 months of treatment.
• The gel base is flammable until dry. Avoid naked flames and do not smoke until the gel has dried on the skin.

Understanding the menopause and transdermal HRT

The menopause is defined as the permanent cessation of menstruation due to the loss of ovarian follicular activity.

In the UK, the average age of natural menopause is 51.

The perimenopause, the transitional phase before the final period, typically begins in the mid-40s and is characterised by declining and fluctuating oestrogen levels.

Symptoms of oestrogen deficiency include vasomotor symptoms (hot flushes and night sweats, experienced by approximately 80% of menopausal women), urogenital atrophy (vaginal dryness, urinary frequency, recurrent urinary tract infections), sleep disturbance, mood changes, difficulty concentrating, joint pain, and reduced bone density.

Hormone replacement therapy works by restoring oestrogen to relieve these symptoms.

HRT can be delivered orally (tablets), transdermally (patches, gels, or sprays), or locally (vaginal creams, pessaries, or rings for urogenital symptoms only).

The route of delivery matters because it affects the medicine's safety profile.

Oral oestrogen passes through the liver before entering the general circulation (first-pass metabolism), which stimulates the liver to produce clotting factors, triglycerides, and binding proteins.

This hepatic stimulation increases the risk of VTE and may affect lipid profiles. Transdermal oestrogen is absorbed directly into the bloodstream through the skin, bypassing the liver entirely.

This avoids the prothrombotic and metabolic effects of first-pass hepatic metabolism, resulting in a lower risk of VTE and a more neutral effect on triglycerides and clotting factors.

What Oestrogel contains and how it works

Oestrogel contains estradiol (17-beta-estradiol), the primary oestrogen produced by the ovaries during the reproductive years.

It is described as body-identical because its molecular structure is identical to the hormone produced naturally in the body.

The gel is formulated in a hydroalcoholic base that facilitates absorption through the skin.

When applied, the alcohol evaporates within a few minutes, leaving a thin film of estradiol on the skin surface.

The estradiol then diffuses through the stratum corneum (the outermost layer of the skin) into the dermal microcirculation, from which it enters the systemic circulation.

The transdermal delivery creates a depot of estradiol in the skin, which provides relatively steady serum estradiol levels over 24 hours.

This contrasts with oral estradiol, which produces a peak in serum levels shortly after ingestion followed by a decline, and which generates higher levels of estrone (a weaker oestrogen) relative to estradiol due to hepatic conversion.

The transdermal route therefore produces a more physiological ratio of estradiol to estrone, more closely resembling the premenopausal hormonal environment.

The pump dispenser mechanism ensures accurate dosing. Each full pump delivers approximately 1.5 g of gel containing 0.75 mg of estradiol.

The standard starting dose is 2 pumps (1.5 mg estradiol), which can be adjusted up or down based on symptom response and, if necessary, serum estradiol measurements.

Why transdermal HRT may be preferred: safety advantages

The most significant clinical advantage of transdermal oestrogen over oral oestrogen is the reduction in VTE risk.

Multiple observational studies, including the large French ESTHER study and a UK case-control study, have consistently shown that transdermal oestrogen does not significantly increase the risk of VTE, whereas oral oestrogen approximately doubles the baseline risk.

This difference is attributed to the avoidance of first-pass hepatic metabolism and the resulting absence of increased clotting factor production.

NICE NG23 recommends that transdermal HRT should be considered for women with VTE risk factors, including a BMI of 30 or above, a personal or family history of VTE, or known thrombophilia.

The MHRA has issued guidance confirming the lower VTE risk with transdermal preparations.

For many women, particularly those with a higher BMI, transdermal oestrogen is the recommended first-line route of HRT delivery.

Evidence regarding stroke risk is less conclusive, but observational data suggest that transdermal oestrogen at standard doses (up to 50 micrograms daily via patches, or equivalent gel doses) is not associated with a significant increase in ischaemic stroke risk, unlike oral oestrogen, which carries a small increased risk.

For women with migraine without aura, transdermal oestrogen may be an option that would not be appropriate as an oral preparation, though this requires specialist assessment.

Transdermal oestrogen also has a more neutral effect on triglycerides and lipid metabolism compared with oral oestrogen, which can raise triglycerides and HDL cholesterol while lowering LDL cholesterol. For women with hypertriglyceridaemia, transdermal delivery is preferred.

Clinical evidence and UK prescribing guidance

The effectiveness of transdermal estradiol in relieving menopausal symptoms is well established.

Clinical trials have shown that Oestrogel significantly reduces the frequency and severity of hot flushes and night sweats within 2 to 4 weeks of starting treatment, with maximal benefit achieved by 8 to 12 weeks.

It also improves vaginal dryness and urogenital symptoms, though women with predominantly urogenital symptoms may benefit from additional local vaginal oestrogen (such as Vagifem or Ovestin).

NICE NG23 recommends HRT as the first-line treatment for vasomotor symptoms and states that benefits generally outweigh risks for women starting treatment under the age of 60 or within 10 years of menopause.

The British Menopause Society (BMS) and the International Menopause Society (IMS) support individualised prescribing, with the choice of preparation, route, and dose tailored to the woman's symptoms, risk factors, and preferences.

When Oestrogel is used with micronised progesterone (Utrogestan) as the progestogen, the combination provides a fully body-identical HRT regimen.

Observational data from France (the E3N cohort study) suggest that the combination of transdermal estradiol with micronised progesterone is associated with a lower breast cancer risk than oral oestrogen combined with synthetic progestogens, though randomised controlled trial data are lacking.

This combination has become the most commonly prescribed HRT regimen in the UK and is supported by the BMS and NICE.

Oestrogel compared with other transdermal HRT options

Several transdermal oestrogen preparations are available in the UK. Oestrogel is a gel applied once daily via a pump dispenser.

Sandrena is another estradiol gel, available in single-dose sachets (0.5 mg and 1 mg).

Estradot, Evorel, and FemSeven are estradiol patches, which are applied to the skin and changed once or twice weekly. Lenzetto is an estradiol transdermal spray.

All transdermal preparations share the advantage of bypassing first-pass hepatic metabolism and carry a similarly low VTE risk.

Gels offer flexibility in dose adjustment (by changing the number of pump applications) and avoid the skin reactions (redness, itching, adhesion problems) that some women experience with patches.

Patches, however, are applied less frequently and may be preferred by women who find daily gel application inconvenient. Sprays offer another daily application option.

The choice between these preparations depends on personal preference, lifestyle, and tolerability.

Application instructions

Prime the pump before first use by pressing it several times until gel is dispensed.

Apply the prescribed number of pump doses (usually 2) to clean, dry, intact skin on the upper arms, shoulders, or inner thighs.

Use a different site each day to minimise the risk of local skin irritation.

Do not apply to the breasts, face, or vulvar area, or to broken, sunburned, or irritated skin.

Spread the gel thinly over a large area of skin (approximately 2 hand-size areas). Allow it to dry for approximately 5 minutes before dressing.

Do not wash the application area for at least 1 hour after applying the gel.

Wash your hands thoroughly with soap and water immediately after application to prevent transfer to other people.

Cover the application site with clothing once dry to prevent accidental skin-to-skin transfer, particularly to children.

Cases of premature puberty in young children exposed to transdermal oestrogen through contact with a treated adult have been reported.

If accidental contact occurs, the affected person should wash the exposed skin area immediately with soap and water.

Side effects of Oestrogel

Common side effects

Breast tenderness is the most common side effect and usually improves within the first 3 months.

Headache, nausea, bloating, skin irritation or redness at the application site, and mood changes may occur.

Breakthrough bleeding or spotting is possible, particularly during the first few months of treatment, and may indicate a need to adjust the progestogen dose or duration.

Cardiovascular and thrombotic risks

As discussed above, transdermal estradiol does not significantly increase VTE risk, in contrast to oral oestrogen. This is one of the principal reasons for choosing a transdermal preparation.

Stroke risk at standard transdermal doses also appears lower than with oral HRT.

However, all HRT carries some cardiovascular considerations, and your prescriber will assess your individual risk profile before and during treatment.

Breast cancer

Breast cancer risk with HRT is influenced primarily by the duration and type of progestogen exposure.

Oestrogen-only HRT (for women without a uterus) carries a smaller risk increase than combined HRT.

When Oestrogel is combined with micronised progesterone, the available evidence (mainly from observational studies) suggests a lower breast cancer risk than when combined with synthetic progestogens such as medroxyprogesterone acetate or norethisterone.

Nonetheless, any combined HRT regimen may increase breast cancer risk with prolonged use. Attend all NHS breast screening invitations and report any breast changes to your GP promptly.

When to seek urgent medical attention

Stop using Oestrogel and seek urgent medical help if you develop sudden leg swelling or pain, chest pain, sudden breathlessness, sudden severe headache, visual disturbance, speech difficulty, arm or leg weakness, or jaundice.

Call 999 if symptoms suggest DVT, PE, or stroke. Contact your GP or call NHS 111 for persistent breakthrough bleeding, breast lumps, or significant mood changes.

Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Progestogen requirement

This is the single most important safety consideration. Women with an intact uterus must use a progestogen alongside Oestrogel.

Unopposed oestrogen stimulates the endometrium and significantly increases the risk of endometrial hyperplasia and cancer. Adequate progestogen opposition is essential.

The most common progestogen prescribed with Oestrogel is micronised progesterone (Utrogestan), given either cyclically (200 mg daily for 12 to 14 days per cycle) or continuously (100 mg daily).

Alternatively, the Mirena intrauterine system provides local progestogen directly to the uterus and is licensed for endometrial protection during HRT.

Contraindications

Oestrogel must not be used in women with known or suspected breast cancer, other oestrogen-dependent malignancies, untreated endometrial hyperplasia, undiagnosed vaginal bleeding, active liver disease, porphyria, active or recent arterial thromboembolic disease, or hypersensitivity to any ingredient.

While VTE history is listed as a contraindication, NICE NG23 notes that transdermal HRT may be considered in women with a history of VTE after specialist assessment, as it does not appear to increase VTE risk further.

Skin transfer

Accidental transfer of estradiol to other people through skin contact is a recognised risk.

Cases of premature breast development and other signs of oestrogen exposure in young children have been reported internationally.

Allow the gel to dry fully, cover the area with clothing, and wash your hands after every application.

Flammability

The hydroalcoholic gel base is flammable until dry. Do not smoke, use naked flames, or go near ignition sources until the gel has fully dried on the skin (approximately 2 to 5 minutes after application).

How to get Oestrogel in the UK

Oestrogel is available on NHS prescription from your GP, menopause clinic, or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Oestrogel has experienced intermittent supply issues in recent years due to high demand following increased awareness of menopause management.

If Oestrogel is temporarily unavailable, your prescriber may offer an alternative transdermal preparation such as Sandrena gel or an estradiol patch.

Sources

• Oestrogel, Summary of Product Characteristics (EMC)
• Estradiol, British National Formulary (BNF)
• NICE NG23: Menopause, diagnosis and management
• Hormone replacement therapy (HRT), NHS
• British Menopause Society
• MHRA Yellow Card Scheme